Desvenlafaxine Er

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI.

Concomitant use increases risk of serotonin syndrome. Contraindicated in patients being treated with linezolid.

Concomitant use increases risk of serotonin syndrome. Contraindicated with intravenous methylene blue.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syndrome occurs.

Concomitant use may potentiate risk of bleeding. Closely monitor for bleeding when desvenlafaxine is initiated or discontinued.

Desvenlafaxine increases atomoxetine exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syndrome occurs.

Desvenlafaxine increases desipramine exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Desvenlafaxine increases dextromethorphan exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syndrome occurs.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syndrome occurs.

Desvenlafaxine increases metoprolol exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Desvenlafaxine increases nebivolol exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.

Desvenlafaxine increases perphenazine exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syndrome occurs.

Desvenlafaxine increases tolterodine exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syndrome occurs.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syndrome occurs.

Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syndrome occurs.

Concomitant use may potentiate risk of bleeding. Closely monitor for bleeding when desvenlafaxine is initiated or discontinued.

Examples desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine 7.2 Drugs Having No Clinically Important Interactions with desvenlafaxine Based on pharmacokinetic studies, no dosage adjustment is required for drugs that are mainly metabolized by CYP3A4 (e.g., midazolam), or for drugs that are metabolized by both CYP2D6 and CYP3A4 (e.g., tamoxifen, aripiprazole), when administered concomitantly with desvenlafaxine [see CLINICAL PHARMACOLOGY (12.3)].

Examples desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine 7.2 Drugs Having No Clinically Important Interactions with desvenlafaxine Based on pharmacokinetic studies, no dosage adjustment is required for drugs that are mainly metabolized by CYP3A4 (e.g., midazolam), or for drugs that are metabolized by both CYP2D6 and CYP3A4 (e.g., tamoxifen, aripiprazole), when administered concomitantly with desvenlafaxine [see CLINICAL PHARMACOLOGY (12.3)].